ArticleNature communications2026
Meta-amplified dark-field interferometric scattering microscopy.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Label-free optical detection of nanometer-scale bioparticles is highly desirable for noninvasive biological studies but challenging due to the weak scattering signals that are difficult to distinguish from the illumination background. Interferometric scattering microscopy (iSCAT) has enabled high-sensitivity imaging by detecting the interference between the particle's scattered light and a reference beam. However, enhancing the detection sensitivity and the image contrast for small particles continues to be a challenge in iSCAT. Here, we introduce meta-amplified dark-field interferometric scattering microscopy (MAD-iSCAT), which leverages a plasmonic metasurface to drastically enhance nanoparticle detection sensitivity in iSCAT. By employing a metasurface comprising sub-diffraction plasmonic meta-atom arrays, MAD-iSCAT generates bright radiation modes that intensely scatter light toward the far field in the presence of a detection nanoparticle, substantially amplifying the sensitivity. In the absence of a nanoparticle, the metasurface produces minimal background due to the dark collective mode, resulting in improved image contrast. We present a theoretical analysis of amplified interferometric imaging using designed metasurfaces and experimentally demonstrate enhancements in contrast and signal-to-noise ratio for detecting dielectric nanoparticles, exosomes, and proteins. Our approach offers broad applications in label-free biosensing and optical mass spectrometry, enabling significantly improved throughput and sensitivity.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.